GLP-1 agonist initiators had a significantly higher likelihood of undergoing thyroid ultrasonography at 6 and 12 months, ...

On June 24, The U.S. Food and Drug Administration(FDA) rejected a citizen petition filed in August 2003 regarding bioequivalence of levothyroxine sodium products and approved first-time generic ...

TED is a rare autoimmune disorder in which the muscles and fatty tissues behind the eye become inflamed, causing the eyes to ...

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...

Red Dye number 3 has been banned by the FDA due to its potential link to cancer in animals, but it is not a significant ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release ...

Thyroid diseases affect about 42 million people in India. Main signs of an overactive thyroid include weight loss and ...

“It can cause gastrointestinal issues if not needed,” warns Sharp.

Linsitinib is an oral small molecule that inhibits the activity of insulin-like growth factor-1 receptor (IGF-1R). It is believed that inhibition of IGF-1R may help reduce orbital inflammation and ...

Western Nevada College psychology professor Dr. Rebecca Bevans is gaining national recognition for her research on the ...